Corrigendum 2 for acn3.753

Abstract

To our knowledge, this is the first randomized controlled study to investigate the effect of PRM in patients with iRBD. The results found that neither low-dose nor higher-dose PRM improved the frequency or severity of RBD symptoms over the 4-week trial period, and there were no significant differences from the placebo in the primary or secondary outcomes. Although the difference in the RBDQ-KR Factor 2 score decreased from 36.4 to 31.8 at 4 weeks after treatment with PRM 6 mg/day, the standard deviation was relatively high and its P value did not show a trend toward statistical significance (P = 0.477).